ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1295

The Prevalence of Inflammatory and Structural Lesions on MRI of the Sacroiliac Joints in Patients with Very Early Peripheral Spondyloarthritis

Gaëlle Varkas1, Philippe Carron2, Heleen Cypers1, Dirk Elewaut1, Lennart Jans3 and Filip van Den Bosch4, 1Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Department of Radiology, Ghent University Hospital, Ghent, Belgium, 4Rheumatology, Ghent University Hospital, Ghent, Belgium

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Arthritis, bone marrow lesions, magnetic resonance imaging (MRI) and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the prevalence of inflammatory and structural lesions on MRI of the sacroiliac joints (SIJ) in patients with peripheral spondyloarthritis (PSpA) in a very early stage of the disease.

Methods: Baseline data originated from the double-blind RCT with golimumab in 60 patients (CRESPA), who were diagnosed with PSpA and had a symptom duration <3 months. MRI SIJ was performed at baseline. Peripheral arthritis, dactylitis or enthesitis combined with ≥1 SpA feature (uveitis, psoriasis, IBD, preceding infection, HLAB27 or sacroiliitis on imaging) was necessary for inclusion. However, all patients already fulfilled the classification criteria without data on imaging of the SIJ. Bone marrow edema (BME) of the SIJ was quantified using the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system. Besides BME of the SIJ, all MRIs were also scored for other inflammatory lesions such as enthesitis and capsulitis. Structural MRI lesions of the SIJ such as subchondral sclerosis, erosions, periarticular fat and ankylosis were also assessed. Hip evaluation consisted of the presence of joint effusion, BME, enthesitis and cortical aberrations.

Results:  Although not the reason for encounter, 7 out of 60 patients reported ever having inflammatory back pain (IBP) at inclusion or in the past, with median Visual analogue scores (VAS) of 2.0 (range 0.0- 9.0) for back pain. Overall, 35% of patients (21/60) exhibited BME of the SIJ and fulfilled the definition of a positive MRI by ASAS, with median SPARCC score of 8.0 (range 2.0-37.0). Only 3 out of 7 patients with IBP exhibited BME on MRI SIJ. Therefore, almost 86% of patients (18/21) with active sacroiliitis did not exhibit symptoms of IBP. Median VAS back pain in patients with sacroiliitis compared to patients without sacroiliitis respectively reached 2.0 and 1.0 (P=NS). Pelvic enthesitis was present in 23.8% (5/21) of patients with an ASAS positive MRI SIJ and in 10.3% (4/39) of patients with negative MRI. None of the patients exhibited enthesitis of the L5 spinous process, iliac crest, anterior superior iliac spine or ramus pubis. None of the patients exhibited thorax enthesitis.

Conclusion: Even in early diagnosed peripheral SpA patients, over 1/3 exhibited BME suggestive of acute sacroiliitis and structural lesions of the SI joints. Our findings underscore the importance of sacroiliitis as the cornerstone feature within the SpA-concept, even in asymptomatic patients.


Disclosure: G. Varkas, None; P. Carron, None; H. Cypers, None; D. Elewaut, None; L. Jans, None; F. van Den Bosch, AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, UCB Pharma, 5,AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Pfizer, UCB Pharma, 8.

To cite this abstract in AMA style:

Varkas G, Carron P, Cypers H, Elewaut D, Jans L, van Den Bosch F. The Prevalence of Inflammatory and Structural Lesions on MRI of the Sacroiliac Joints in Patients with Very Early Peripheral Spondyloarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-inflammatory-and-structural-lesions-on-mri-of-the-sacroiliac-joints-in-patients-with-very-early-peripheral-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-inflammatory-and-structural-lesions-on-mri-of-the-sacroiliac-joints-in-patients-with-very-early-peripheral-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology